Article (Scientific journals)
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study
Reginster, Jean-Yves; Wilson, K. M.; Dumont, Etienne et al.
2005In Journal of Clinical Endocrinology and Metabolism, 90 (9), p. 5018-5024
Peer Reviewed verified by ORBi
 

Files


Full Text
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women Results from the monthly oral pilot study.pdf
Publisher postprint (237.52 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Context: Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing. Objective: The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandronate. Design: A randomized, 3-month, double-blind, placebo-controlled, phase I study (Monthly Oral Pilot Study) was conducted. Setting: The study was conducted at five clinical trial centers in the United Kingdom and Belgium. Patients or Other Participants: Subjects were postmenopausal women (age, 55 - 80 yr; >= 3 yr post menopause; n = 144). Intervention(s): Once-monthly oral ibandronate 50, 100, or 150 mg or placebo was used. After the first cycle, the 50-mg arm was split, with participants continuing on either 50 or 100 mg. Main Outcome Measure(s): Primary outcome measures were safety, serum and urinary C-telopeptide (CTX), and serum ibandronate AUC(0-infinity). Results: Once- monthly oral ibandronate was well tolerated, with a similar overall and upper gastrointestinal safety profile to placebo. Once- monthly ibandronate was also highly effective in decreasing bone turnover; substantial reductions from baseline in serum CTX (-56.7% and -40.7% in the 150- and 100- mg arms, respectively; P < 0.001 vs. placebo) and urinary CTX (-54.1% and -34.6%, respectively; P < 0.001 vs. placebo) were observed at d 91 (30 d after the final dose). Analysis of the area under the effect curve (d1 - 91) for change from baseline (percent x days) in serum CTX and urinary CTX indicated a dose- response relationship. The AUC(0-infinity) for ibandronate increased with dose but not in a dose- proportional manner. Conclusions: These findings indicate a potential role for once-monthly oral ibandronate in the treatment of postmenopausal osteoporosis.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Wilson, K. M.
Dumont, Etienne
Bonvoisin, B.
Barrett, J.
Language :
English
Title :
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study
Publication date :
September 2005
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Soc, Chevy Chase, United States - Maryland
Volume :
90
Issue :
9
Pages :
5018-5024
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 August 2009

Statistics


Number of views
105 (2 by ULiège)
Number of downloads
530 (1 by ULiège)

Scopus citations®
 
55
Scopus citations®
without self-citations
45
OpenCitations
 
38

Bibliography


Similar publications



Contact ORBi